This trial is evaluating whether Treatment will improve 1 primary outcome in patients with Rhinitis, Allergic. Measurement will happen over the course of Change in symptom score from day 0 to day 4 after inoculation with the rhinovirus.
This trial requires 60 total participants across 3 different treatment groups
This trial involves 3 different treatments. Treatment is the primary treatment being studied. Participants will all receive the same treatment. There is no placebo group. The treatments being tested are in Phase 2 and have already been tested with other people.
Patients from any state can participate in this trial, so long as they are able to attend all treatment sessions.
In order to understand how insurance coverage works for this trial, you will need to contact the study coordinator.